Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Milana 2022 | Pharma | 56.4% | 99th pct | 110 |
| H Bi-Georgia | Pharma | 39.9% | 91st pct | 110 |
| Alpaparm | Pharma | 34.4% | 84th pct | 110 |
| Mediniusi | Pharma | 10.9% | 41st pct | 110 |
| Ermed Georgia | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Mediniusi | Alpaparm | Milana 2022 | H Bi-Georgia | Ermed Georgia |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 16.7% | 54.5% | 60.8% | 70.0% | — |
| EBITDA Margin | 10.9% | 34.4% | 56.4% | 39.9% | — |
| EBITDAR | 365 | 1,178 | 1,673 | 1,174 | — |
| EBITDAR Margin | 11.9% | 39.8% | 56.9% | 41.3% | — |
| EBIT Margin | 10.9% | 34.2% | 56.4% | 39.7% | — |
| Net Profit Margin | 8.9% | 29.0% | 59.8% | 35.6% | — |
| Operating Expense % of Sales | 5.8% | 20.1% | 4.4% | 30.0% | — |
| Returns | |||||
| Return on Assets (ROA) | 7.7% | 36.7% | 65.6% | 35.4% | — |
| Return on Equity (ROE) | 8.3% | 44.0% | 77.0% | 50.0% | — |
| ROIC [EBIT / Invested Capital] | 10.0% | 59.5% | 77.0% | 57.1% | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 4.9% | 0.0% | 0.0% | 0.0% | — |
| Debt-to-Equity | 0.05x | 0.00x | 0.00x | 0.00x | — |
| Debt-to-EBITDA | 0.51x | 0.00x | 0.00x | 0.00x | — |
| Equity-to-Assets | 92.4% | 83.2% | 85.1% | 70.8% | — |
| Net Debt | 80 | -246 | -134 | -46 | — |
| Cash & Equivalents | 92 | 246 | 134 | 46 | — |
| Total Debt | 172 | N/A | N/A | N/A | — |
| Liquidity & working capital | |||||
| Current Ratio | 32.62x | 0.00x | 6.72x | 3.40x | — |
| Quick Ratio | 32.62x | 0.00x | 6.72x | 3.40x | — |
| Cash Ratio | 0.97x | 0.63x | 0.33x | 0.06x | — |
| Total Current Assets | 3,114 | 0 | 2,686 | 2,844 | — |
| Total Current Liabilities | 95 | 392 | 400 | 837 | — |
| Inventory | N/A | N/A | N/A | N/A | — |
| Trade Receivables | 1,953 | 758 | 2,543 | 2,235 | — |
| Trade Payables | 90 | 380 | 399 | 826 | — |
| Net Working Capital | 3,019 | -392 | 2,286 | 2,007 | — |
| Net Working Capital % of Revenue | 98.1% | -13.3% | 77.7% | 70.6% | — |
| Trade Working Capital | 1,863 | 378 | 2,144 | 1,409 | — |
| Trade Working Capital % of Revenue | 60.6% | 12.8% | 72.9% | 49.5% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | — |
| Receivables Turnover | 1.58x | 3.90x | 1.16x | 1.27x | — |
| Days Sales Outstanding (DSO) | 231.7 | 93.5 | 315.4 | 286.9 | — |
| Payables Turnover | 28.45x | 3.55x | 2.89x | 1.03x | — |
| Days Payable Outstanding (DPO) | 12.8 | 102.9 | 126.1 | 353.2 | — |
| Cash Conversion Cycle | 218.9 days | -9.4 days | 189.4 days | -66.3 days | — |
| Asset Turnover | 0.87x | 1.26x | 1.10x | 0.99x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 48 | 2,287 | 2,028 | -165 | — |
| Free Cash Flow (OCF − Capex proxy) | 48 | 2,287 | 2,028 | -165 | — |
| Cash Conversion (OCF / EBITDA) | 14.2% | 224.6% | 122.3% | -14.5% | — |
| Dividends Declared | N/A | N/A | N/A | N/A | — |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | — |